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Abstract
Type I interferons (IFN) comprise a family of cytokines that signal through a common cellular receptor to induce a plethora
of genes with antiviral and other activities. Recombinant IFNs are used for the treatment of hepatitis C virus infection,
multiple sclerosis, and certain malignancies. The capability of type I IFN to suppress virus replication and resultant
cytopathic effects is frequently used to measure their bioactivity. However, these assays are time-consuming and require
appropriate biosafety containment. In this study, an improved IFN assay is presented which is based on a recombinant
vesicular stomatitis virus (VSV) replicon encoding two reporter proteins, firefly luciferase and green fluorescent protein. The
vector lacks the essential envelope glycoprotein (G) gene of VSV and is propagated on a G protein-expressing transgenic
cell line. Several mammalian and avian cells turned out to be susceptible to infection with the complemented replicon
particles. Infected cells readily expressed the reporter proteins at high levels five hours post infection. When human
fibroblasts were treated with serial dilutions of human IFN-b prior to infection, reporter expression was accordingly
suppressed. This method was more sensitive and faster than a classical IFN bioassay based on VSV cytopathic effects. In
addition, the antiviral activity of human IFN-l (interleukin-29), a type III IFN, was determined on Calu-3 cells. Both IFN-b and
IFN-l were acid-stable, but only IFN-b was resistant to alkaline treatment. The antiviral activities of canine, porcine, and
avian type I IFN were analysed with cell lines derived from the corresponding species. This safe bioassay will be useful for
the rapid and sensitive quantification of multi-species type I IFN and potentially other antiviral cytokines.
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Introduction
IFN-a and IFN-b are structurally related cytokines of the type I
interferon family which mediate an early innate immune response
to viral infections. There are 13 distinct IFN-a genes present in the
human genome, and a single gene encoding for IFN-b. These
genes are transcriptionally activated in cells sensing a virus
infection through pattern recognition receptors such as the retinoic
acid inducible gene I (RIG-I) helicase. Following secretion, IFN-a
and IFN-b act similarly by binding to a common, ubiquitously
expressed IFN-a/b receptor resulting in the activation of the
JAK/STAT signal transduction pathway and transcription of
‘‘IFN-induced genes’’ [1,2]. Several of these genes encode for
proteins with strong antiviral activity, i.e. Mx protein, protein
kinase R, and 29-59oligo(A) synthetase [3]. Due to their autocrine
action, type I IFN may attenuate virus replication in infected cells.
Probably more important is the paracrine action of type I IFN,
which induces an antiviral state in previously uninfected cells,
thereby blocking virus dissemination in the organism. In addition
to this ‘‘classical’’ antiviral function, type I IFNs are known to
affect cell proliferation and differentiation, to modulate the
immune response, to inhibit angiogenesis, and to promote
apoptosis [4,5]. Genetically engineered type I IFNs are currently
in clinical use for the treatment of multiple sclerosis [6], chronic
hepatitis C virus infection [7], and certain types of cancer [8,9]. An
issue of increasing importance is the determination of neutralizing
antibodies that are induced in some patients following recombi-
nant IFN therapy [10].
Apart from IFN-a/b, cytokines such as IFN-c (type II IFN) and
IFN-l (type III IFN) exhibit antiviral activities, although they bind
to distinct receptors. In particular, type III IFNs induce
transcriptional activation of antiviral genes similar to those
activated by type I IFN. Type III IFNs act primarily on epithelial
cells [11] and probably play an important role in the innate
immune response of epithelial tissues to virus infections [12,13].
The accurate determination of antiviral IFN activity is a
cumbersome issue. In the ‘‘classical’’ bioassay, serial dilutions of
both a test sample with unknown IFN activity and a type I IFN
standard are incubated with an appropriate cell line prior to
infection with a cytolytic virus such as vesicular stomatitis virus
(VSV), encephalomyocarditis virus, or Sendai virus [14,15]. The
reciprocal value of the highest type I IFN dilution mediating
protection of 50% of the cells from virus-induced cytopathic effects
(CPE) is defined as one unit of type I IFN per volume. This
classical IFN bioassay is time-consuming because the CPE
normally needs 24 hours or more to develop. A faster readout
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proteins such as green fluorescent protein (GFP) or firefly
luciferase [16,17,18,19]. However, any work with live virus
requires appropriate biosafety containment. For example, a
recently published IFN bioassay can only be performed in
biosafety level 3 (BSL-3) facilities, because the test makes use of
a recombinant Rift Valley Fever virus [19]. Viral replicon-based
bioassays that take advantage of disabled propagation-incompe-
tent viruses may provide an attractive alternative to live virus-
based bioassays. A human hepatoma cell line harbouring a
selectable hepatitis C virus replicon has been successfully
employed for the measurement of type I IFN from patients with
chronic hepatitis C virus infection [20]. However, as type I IFNs
act in a species-dependent manner, this system may not be
applicable to animal IFNs. Transgenic cell lines expressing a
reporter gene under control of an IFN-responsive promoter may
also be used to determine IFN activity under biosafe conditions
[21,22]. However, it is difficult to simply relate transcriptional
reporter gene activation to antiviral activity.
In this report, a novel type I IFN bioassay is presented, which is
based on BSL-1-classified VSV replicon particles. The assay is
highly sensitive and quantifiable due to the expression of a firefly
luciferase reporter gene. In addition, the assay can be rapidly
performed within 6 to 7 hours and may be used to determine the
antiviralactivityofIFNsfromhumansaswellasotherspecies.Thus,
this bioassay may be of general interest for all those who want to
determine the antiviral activity of cytokines such as type I IFNs.
Materials and Methods
Cells
BHK-21 cells were obtained from the German Cell Culture
Collection (DSZM, Braunschweig, Germany) and grown in Earle’s
minimal essential medium (EMEM) supplemented with 5% fetal
bovine serum (FBS). BHK-G43, a transgenic BHK-21 cell clone
expressing VSV G protein in a regulated manner, was maintained
as described previously [23]. The porcine kidney cell line PK-15
(ATCC, Manassas, VA) was propagated in Dulbecco’s modified
Eagle medium supplemented with nonessential amino acids,
1 mM Na-pyruvate and 5% horse serum. D-17 canine osteosar-
coma cells (ATCC), Calu-3 human lung adenocarcinoma cells
(ATCC), and NHDF normal human dermal fibroblasts (Lonza,
Cologne, Germany) were maintained in EMEM with 10% FBS.
The UMNSAH/DF-1 (DF-1) chicken fibroblast cell line (ATCC)
was maintained in Dulbecco’s Modified Eagle’s Medium and 10%
FBS. All cell lines were cultured at 37uC in a humidified
atmosphere containing 5% CO2, except DF-1 cells which were
kept at 39uC. BALB 3T3 fibroblasts (subclone A31) were kindly
provided by N. Pringle, University College, London, UK, and
maintained in Dulbecco’s Modified Eagle’s Medium.
Interferons
Human and murine IFN-b and human IFN-l (IL-29) were
purchased from PBL InterferonSource (Piscataway, NJ). Recom-
binant porcine IFN-a1 [24] was kindly provided by Nicolas Ruggli
(IVI, Mittelha ¨usern, Switzerland). Recombinant chicken IFN-a
[25] was kindly provided by Peter Sta ¨heli (University of Freiburg,
Germany). Canine IFN-b [26] was kindly provided by Philippe
Plattet (Department of Clinical Research and Veterinary Public
Health, University of Bern).
Generation of VSV*DG(Luc) replicon particles
A plasmid-based rescue system [27] was used to generate a G-
deleted VSV driving expression of firefly luciferase and eGFP. The
previously described genomic plasmid pVSV*DG(HA) containing 6
distinct transcription units (N-P-M-HA-eGFP-L) [28] was modified
by replacing the influenza virus HA gene in the fourth position with
eGFP taking advantage of MluI and BstEII endonuclease restriction
sites upstream and downstream of the HA ORF, respectively. The
firefly luciferase gene was amplified from the pBI-L plasmid
(Clontech) by Pfu PCR and inserted into the fifth transcrition unit
using XhoIa n dNheI endonuclease restriction sites. The resulting
plasmid was designated pVSV*DG(Luc) and contained 6 genes in
the order N-P-M-eGFP-Luc-L (Fig. 1).
For generation of VSV*DG(Luc) replicon particles, BHK-G43
helper cells were grown in 100-mm diameter culture dishes to 90%
confluence and infected with recombinant modified vaccinia virus
Ankara (5 pfu per cell) expressing T7 RNA polymerase (MVA-T7,
a gift of Gerd Sutter, Mu ¨nchen, Germany). MVA-T7 has been
classified by the German Central Committee for Biosafety as a
BSL-1 organism (reference number 6790-10-14). Ninety minutes
post infection, the medium was replaced with fresh EMEM
containing 5% FBS and 10
29 M mifepristone (Sigma-Aldrich,
Buchs, Switzerland) to induce VSV G expression [23]. Subse-
quently, the cells were transfected with 10 mg of pVSV*DG(Luc),
3 mg of pTM1-N, 5 mg of pTM1-P, and 2 mg of pTM1-L [28]
using Lipofectamine
TM 2000 transfection reagent (Invitrogen,
Basel, Switzerland). The cells were trypsinized 24 hours post
transfection and seeded into T75 flasks along with an equal
number of fresh BHK-G43 cells. The cells were further incubated
at 37uC for 24 hours in the presence of 10
29 M mifepristone. The
cell culture supernatant was clarified by low-speed centrifugation
and passed through a 0.20-mm-pore size filter to deplete vaccinia
virus. VSV*DG(Luc) was further propagated on mifepristone-
induced BHK-G43 cells and stored frozen at 270uC. To
determine infectious virus titers, confluent BHK-21 grown in 96-
well microtiter plates were inoculated in duplicate with 40 mlo f
serial tenfold virus dilutions for 1 h at 37uC. The wells additionally
received 60 ml of EMEM and were incubated for 20 h at 37uC.
The infectious titers were calculated according to the number of
GFP-expressing cells/well and expressed as fluorescence-forming
units per milliliter (ffu/ml).
MVA-T7 was titrated on DF-1 cells grown in 96-well microtiter
plates. The cells were inoculated with tenfold serial virus dilutions for
90 min and overlayed with medium containing 0.9% methylcellu-
lose. Following incubation for 48 h at 39uC, the cells were fixed with
3%paraformaldehyde,permeabilizedwith0.25%TritonX-100,and
subsequently incubated with the TW2.3 monoclonal antibody
directed to the vaccinia E3L protein (kindly provided by Jonathan
Yewdell, NIH, Bethesda, USA) and anti-mouse IgG conjugated to
horseradish peroxidase (DAKO). Infected cell foci were visualized
with the AEC peroxidase substrate and expressed as plaque-forming
units per milliliter (pfu/ml). Using this assay, the final VSV replicon
particle preparations proved to be free of MVA-T7.
Bioassays for determining antiviral activity
Serial twofold or fourfold dilutions of type I IFN were prepared
with cell culture medium containing 5% FBS. The IFN dilutions
(100 ml) were added in quadruplicates to confluent cells grown in
96-wells (5610
4 cells/well) and incubated for either 1, 2, 4, or
20 hours at 39uC (DF-1 cells) or 37uC (all other cell lines). The
cells were infected with VSV*DG(Luc) (m.o.i. of 5) and incubated
for 5 hours at 37uC. The medium was aspirated and 30 mlo f
luciferase lysis buffer (Biotium Inc., Hayward, CA) was added to
the cells. The cell lysates were stored at 220uC. Firefly luciferase
activity was determined with a Centro LB 960 luminometer
(Berthold Technologies). Luminescence was recorded for 1 s
following injection of 30 ml of D-luciferin substrate (Biotium) to
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relative antiviral activity was calculated according to the following
formula: Antiviral Activity (%)=100 - [(RLU+IFN – Blank)6100/
(RLU2IFN - Blank)]. Mock-infected cell lysates served as blanks
and relative light units (RLU) detected with these samples were
subtracted from the readings taken from VSV*DG(Luc)-infected
cell lysates. RLU+IFN represents the RLU values from IFN-treated
cells and RLU2IFN the readings taken from reference cells, which
had not received any type I IFN.
A conventional type I IFN bioassay was performed by incubating
96-well cell cultures for 20 hours with twofold dilutions of type I IFN as
described above. The cells were infected with propagation-competent
VSV (m.o.i. of 1 pfu/cell) and incubated until a cytopathic effect (CPE)
was evident in mock-treated control cells. The cells were washed twice
with PBS and stained for 1 h with 0.1% crystal violet in 10% formalin.
The plates were washed with tap water to remove excess crystal violet
and dried. The dye was dissolved by adding 100 ml of 70% ethanol to
each well. The absorbance of crystal violet at 595 nm was determined
with a microplate reader. The IFN titer was calculated as the reciprocal
of the last IFN dilution causing 50% inhibition of virus-induced CPE
(50 % reduction of absorbance at 595 nm compared to mock-infected
cells) and was expressed as IFN units per volume. Alternatively,
antiviral activity was calculated according to the following formula:
Antiviralactivity(%)=(OD595+IFN–OD5952IFN)6100/(OD595Mock
– OD5952IFN). OD595+IFN and OD5952IFN represent the absor-
bance of IFN-treated and non-treated cells following infection with
VSV and staining with crystal violet, respectively. OD595Mock denotes
the absorbance of non-infected cells.
Statistical analysis
Mean values and standard deviation were calculated. Statistical
analysis was performed using the paired Student’s t-test. P,0.05
was considered significant.
Results
Generation of the VSV*DG(Luc) replicon
Previously, a VSV replicon vector was generated by replacing
the glycoprotein G gene of VSV with the hemagglutinin (HA) gene
Figure 1. Expression of firefly luciferase and GFP reporter genes by a propagation-incompetent VSVDG replicon. (a) Genome maps of
authentic VSV and recombinant VSV*DG(Luc) vector. VSV*DG(Luc) lacks the glycoprotein (G) gene and drives expression of both enhanced green
fluorescent protein (GFP) and firefly luciferase (Luc). (b) Cell lines derived from different species were infected with 4 ffu/cell of VSV*DG(Luc) (1
st
cycle). Sixteen hours post infection, the undiluted cell culture supernatant was passed to fresh cells (2
nd cycle). GFP expression in live cells was
monitored 6 h post infection using an inverse fluorescence microscope. Bar, 100 mm. (c) Firefly luciferase activity in BHK-21 cell lysates at different
times post infection with 4 ffu/cell of VSV*DG(Luc). (d) Firefly luciferase levels in BHK-21 cell lysates 5 h post infection by VSV*DG(Luc) with the
indicated multiplicities of infection (m.o.i.).
doi:10.1371/journal.pone.0025858.g001
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unit into the HA-L intergenic junction to drive expression of a
modified GFP gene [28]. In the present work, this vector was
modified by inserting the firefly luciferase gene into the
transcription unit at position 5 (thereby replacing the GFP gene)
and exchanging the HA gene with the GFP gene (Fig. 1a). The
resulting vector, VSV*DG(Luc), was propagated on BHK-G43
helper cells which express the VSV G protein in an inducible
manner [23]. Up to 10
9 virus replicon particles (VRP) were
released into the cell culture supernatant 24 h post infection (data
not shown). Several mammalian and avian cells were found to be
susceptible to infection with the VRPs in line with previous
observations on the very broad cell tropism of VSV [29]. Infected
cells were readily detected (5 to 6 h post infection) by means of
GFP reporter expression (Fig. 1b). However, non-helper cells were
unable to complement the VSV G deletion and thus could not
produce infectious progeny virus. Importantly, VSV*DG(Luc) did
not induce type I IFN in the cell lines analysed (data not shown).
This can be ascribed to the host shut-off activity of the VSV matrix
protein [30].
Infection of BHK-21 cells with VSV*DG(Luc) using a
multiplicity of infection (m.o.i.) of 4 ffu/cell resulted in increasing
firefly luciferase reporter activity with time (Fig. 1c). In all
subsequent experiments, luciferase activity was generally recorded
at 5 h post infection as the signal-to-noise ratio was sufficiently
high at this time. When BHK-21 cells were infected with different
virus dose rates, luciferase reporter activity increased linearly
between 0.004 and 40 ffu/cell (Fig. 1d). Although 95% of the cells
showed GFP fluorescence following infection with an m.o.i. of
4 ffu/cell (not shown), an m.o.i. of 40 ffu/cell caused an even
tenfold higher luciferase activity suggesting that multiple infections
add to the overall replication/transcription rate of the virus
genome in a single cell. In all subsequent experiments an m.o.i. of
5 ffu/cell was generally used, as this guaranteed a signal-to noise
ratio of about 4 log10.
Quantification of type I IFN antiviral activity
The luciferase reporter activity in VSV*DG(Luc)-infected cells
depends on the replication/transcription levels of the RNA
replicon. Thus, a reduction in viral genome replication as a
consequence of type IFN action should lead to correspondingly
lower luciferase levels. To test this hypothesis, normal human
dermal fibroblasts (NHDF) were incubated for various time
periods with serial dilutions of human IFN-b before infection
with VSV*DG(Luc). A dose-dependent effect of IFN-b on firefly
luciferase reporter activity was observed after 1 hour of incubation
(Fig. 2a). About 1 unit of IFN-b led to 50% suppression of
luciferase activity. Extending the incubation time to 2 hours did
not further improve the sensitivity of the test (p.0.05 for the 0.08
to 1.25 IFN units range). However, if the cells were treated for
20 hours, the dose response curve was significantly shifted to lower
IFN units (p#0.001 for the 0.02 to 20 units range). Approximately
0.05 units of IFN-b were now sufficient to suppress reporter
activity by 50%. These results indicate that an IFNb-induced
antiviral state in NHDF cells can be detected as early as 1 hour
after addition of IFN-b, although the sensitivity of the assay is
higher if the cells were incubated with IFN-b for prolonged time.
VSV*DG(Luc) was also used to quantify the activities of porcine
and chicken IFN-a. While the dose response curve of chicken IFN-
a on DF-1 chicken fibroblasts (Fig. 2b) was similar to the one of
human IFN-b on NHDF (Fig. 2a), porcine IFN-a showed a
different kinetics on PK-15 porcine kidney cells. In these cells, a
full antiviral state was accomplished only after 20 hours of
treatment indicating that PK-15 cells respond rather slowly to
the action of type I IFN (Fig. 2c). Thus, the assay is applicable to
type I IFN from different species but may perform differentially on
distinct cell types.
Figure 2. Determination of mammalian and avian type I IFN
bioactivity. (a) NHDF (human fibroblasts), (b) DF-1 (chicken fibro-
blasts), and (c) PK-15 (porcine kidney) cells in 96-well plates were
incubated for the indicated times with fourfold serial dilutions of type I
IFN from the homologous species and subsequently infected with
VSV*DG(Luc) (5 ffu/cell). Five hours post infection, the cells were lysed
and firefly luciferase activity was recorded. Reference cells did not
receive any type I IFN and demonstrated no antiviral activity. The axes
of abscissas indicate the activities of the type I IFNs as determined with
a conventional CPE-based IFN bioassay.
doi:10.1371/journal.pone.0025858.g002
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of unknown activity were tested against a commercial IFN-b
standard and the results were compared with those obtained with
a conventional IFN bioassay based on VSV cytotoxicity. Human
type I IFN was induced in NHDF human fibroblasts following
infection with VSV*Mq [30]. This propagation-competent virus
expresses a mutant matrix protein that is unable to block the
nucleocytoplasmic RNA transport of the cell. Before the samples
were tested for antiviral activity, VSV*Mq was inactivated for
30 min with 0.1 M HCl to avoid any interference with the
bioassay (see also the section on thermal and pH stability of IFN).
When the VSV*DG(Luc) replicon bioassay was used, about
0.8 pg/ml of a commercial IFN-b standard resulted in 50%
antiviral activity. In consideration of the final dilution producing
50% antiviral activity, the type I IFN concentration of two test
samples was defined as 4000 pg/ml and 1440 pg/ml, respectively
(Fig. 3a). When the samples were tested with the conventional
bioassay (Fig. 3b), the values were in the same range (5000 and
1500 pg/ml), indicating that both assays principally agree.
Nevertheless, the replicon-based bioassay proved to be more
sensitive than the conventional one as lower amounts of type I IFN
were sufficient to reduce the luciferase reporter activity by 50%
(compare curves shown in Fig. 3a with those in Fig. 3b).
Characterization of the species-dependent action of type
I IFN
The species-dependent action of type I IFN was analysed by
incubating human, canine, murine, and chicken cells for 20 hours
with 5 units of type I IFN from either the homologous species or a
different one. When cells were treated with the respective
homologous IFN an antiviral state was induced as indicated by
the lack of GFP expression 6 hours post infection with
VSV*DG(Luc) (Fig. 4a). In contrast, untreated cells or cells that
Figure 3. Validation of the VSV*DG(Luc) replicon bioassay. Serial twofold dilutions of IFN-b standard (starting with 100 pg/ml) and of two
different test samples containing type IFN of unknown activity (starting with dilution 1/100) were prepared and incubated with NHDF for 20 h at
37uC. (a) Five hours post infection with VSV*DG(Luc) (m.o.i.=5), the cells were lysed and firefly luciferase activity recorded. The antiviral activity
relative to infected but non-treated cells was calculated. (b) Fourty-eight hours post infection with VSV (m.o.i.=1), the cells were fixed with formalin
containing 0.1% crystal violet, washed with water, and dried. The dye was dissolved in 70% ethanol before absorbance at 595 nm was recorded. The
relative antiviral activity (%) was calculated.
doi:10.1371/journal.pone.0025858.g003
Figure 4. Type I IFNs act in a species-specific manner. (a) Cells derived from different species were treated for 20 h with the indicated type I
IFNs (5 units/well) and subsequently infected with VSV*DG(Luc). Expression of GFP was monitored 6 h post infection by fluorescence microscopy. Bar,
30 mm. (b) NHDF were incubated for 20 h with serial fourfold dilutions of human, porcine and murine type I IFNs. The cells were subsequently
infected with VSV*DG(Luc) for 5 h and firefly luciferase activity was recorded in the cell lysates.
doi:10.1371/journal.pone.0025858.g004
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protected and showed GFP expression accordingly. To compare
the effects of different concentrations of homologous and
heterologous type I IFN on human cells, we treated NHDF for
20 hours with serial dilutions of human, porcine, and murine type
I IFN prior to infection with VSV*DG(Luc). Firefly luciferase
reporter activity in infected cell lysates indicated that porcine IFN-
a is active in NHDF albeit at reduced levels compared to human
IFN-b (Fig. 4b; p#0.0049 for the 0.008 to 2.0 units range). Murine
IFN-b showed an even lower activity on NHDF (ED50 of 500 units
per 5610
4 NHDF cells; p#0.0003 for the 0.008 to 500 units
range). These results demonstrate that type I IFNs act in a species-
dependent manner and accentuate the need for selecting
appropriate cell lines to determine their activity.
Thermal and pH stability of type I and type III IFN
We often encounter the problem that the activity of type I IFN
has to be determined in a sample containing live virus. As virus
infection may interfere with the bioassay, it has to be inactivated
before the assay is performed, preferentially without touching the
activity of type I IFN. As many viruses can simply be inactivated
by treatment with heat, we first analysed the thermal stability of
human IFN-b using the VSV*DG(Luc) bioassay. The antiviral
activity of human IFN-b was fully maintained when the cytokine
was incubated for 30 min at 50uC (Fig. 5a). At 60uC, 99% of the
activity was preserved (p=0.021). At 70uC, the activity of human
IFN-b dropped to 83% (p=0.0017). Incubation at higher
temperatures (80uC and 90uC) affected the activity more
drastically, although some activity was still left at these
temperatures. Only when human IFN-b was heated to 100uC
for 30 min, activity was completely abolished. In contrast to
human IFN-b, porcine IFN-a was completely inactivated at 70uC
(p,0.0001), whereas human IFN-l (IL-29), a type III IFN,
showed even higher residual activity at 80uC and 90uC( p ,0.001),
suggesting that these cytokines have different physicochemical
properties.
To study the sensitivity of type I and type III IFNs to conditions
of extreme pH, human IFN-b and human IFN-l were treated for
30 min with either 0.1 M HCl, 0.1 M NaOH or H2O, adjusted to
neutral pH, and assayed on NHDF and Calu-3 cells, respectively.
It turned out that the antiviral activity of human IFN-b was not
significantly affected by acid (p.0.05) (Fig. 5b), confirming the
previously noted acid-stability of type I IFNs [31]. IFN-l showed
similar properties as antiviral activity was maintained following
treatment with 0.1 M HCl (Fig. 5c). In contrast, alkaline treatment
significantly reduced the activity of IFN-l (p,0.05 for the 250 2
1 ng/ml range), whereas IFN-b was not affected (p.0.05) (Fig. 5b).
Thus, treatment with acid may be employed to inactivate virus in
a test sample without affecting the activity of type I and type III
IFNs. On the other hand, alkaline may be used to differentiate
between type I and type III IFNs.
Discussion
Conventional bioassays take advantage of the antiviral activity
of type I IFN to measure the inhibition of virus-induced cytopathic
effects in cell culture [14]. In this study, we presented an improved
bioassay by employing a recombinant VSV replicon equipped
with two reporter proteins. This assay proved to be advantageous
over the conventional assay with respect to biosafety, sensitivity,
and time requirements.
The use of cytopathic viruses in conventional type I IFN
bioassays makes appropriate biosafety measures necessary to
reduce the risk of unwanted virus transmission and infection. In
this regard, the VSV*DG(Luc) replicon particles can be regarded
as biosafe. Since the modified VSV genome lacks the envelope
glycoprotein (G) gene, VSV*DG(Luc) is propagated on helper cells
providing the G glycoprotein in trans [23]. The replicon particles
produced on these cells can run a single cycle of infection but
Figure 5. Analysis of type I IFN stability. (a) Human IFN-b and
porcine IFN-a (each at 800 units/ml) were heated for 30 min at the
indicated temperatures and thereafter diluted 1:10 with medium
containing 5% FBS. The heat-treated IFN preparations were incubated
for 20 h with NHDF and PK-15 cells, respectively (8 units per 5610
4
cells). Luciferase reporter activity was determined in cell lysates 5 hours
post infection with VSV*DG(Luc). (b) Human IFN-b and (c) human IFN-l
were incubated for 30 min at 20uC with either 0.1 M HCl, 0.1 M NaOH,
or H2O, and then adjusted to neutral pH. NHDF and Calu-3 cells were
incubated for 20 h with fourfold serial dilutions of HCl/NaOH-treated
IFN-b and IFN-l, respectively, and subsequently infected with
VSV*DG(Luc). Firefly luciferase activity was determined in cell lysates
5 h post infection.
doi:10.1371/journal.pone.0025858.g005
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contributing to biosafety is that the RNA replicon replicates
exclusively in the cytosol and does not produce cDNA interme-
diates. Thus, in the case of an accidental infection any risk of
recombination with or integration into host chromosomal DNA
can be excluded.
Virus preparations that are used for IFN bioassays must not
contain any type I IFN which may distort the results. In addition,
the viruses should not induce IFN in infected reporter cells to
assure that the effects measured are solely due to the exogenous
IFN added. Both criteria are fulfilled for VSV*DG(Luc). The
helper cells used to propagate the replicon particles are derived
from BHK-21 cells, which are defective in the synthesis of type I
IFN [32]. In addition, the VSVDG replicon does not induce type I
IFN in infected reporter cells, because the VSV matrix protein
efficiently blocks the nuclear export of cellular mRNA including
the IFN mRNA [30,33].
Conventional type IFN bioassays often take 24 hours or more to
be completed as they rely on the inhibition of cytopathic effects. In
contrast, the bioassay presented here takes advantage of the firefly
luciferase reporter, which can be detected with high sensitivity long
before a cytopathic effect is apparent. Although the luciferase
reporter enabled us to unambiguously quantify the IFN-mediated
reduction of virus replication, we frequently observed that the
standard deviations for the antiviral activities increased when the
cells weretreatedwith lowamountsoftype I IFN. Thislikelyreflects
the high reporter gene expression at low levels of type I IFN and the
inaccuracy associated with pipetting small volumes (6 ml).
The engagement of a common cellular receptor by type I IFNs
leads to activation of the JAK/STAT pathway and transcriptional
induction of several genes with antiviral activity [1,2]. It is
common practice that cells are incubated with type I IFN for
several hours to induce an antiviral state [15,19]. Our findings
suggest that an antiviral state can be detected much earlier. For
example, treatment of NHDF with 1 unit of human IFN-b for
1 hour and subsequent infection with VSV*DG(Luc) for 5 hours
was sufficient to suppress firefly reporter expression by 50%, even
though the effective dose was further lowered with longer
incubation times. While DF-1 fibroblasts responded to chicken
IFN-a with dose response kinetics similar to the one observed with
human IFN-b on NHDF, PK-15 cells responded to porcine type I
IFN in a much slower way. Thus, compared to conventional
bioassays VSV*DG(Luc) may allow quantification of type I IFN in
a considerably shorter time provided an appropriate cell line has
been selected. The selection of a suitable cell line is also important
with respect to the species it is derived from, as full activity of type
I IFN was only observed with cells from the corresponding species.
Since VSV is able to infect a broad spectrum of mammalian and
avian cells, the new bioassay may be used to determine the
bioactivity of type I IFNs from many different animals.
Although type I IFNs are the predominant cytokines with
antiviral activity [34], it cannot be excluded that test samples
contain other cytokines that inhibit VSV replication. Indeed, using
the VSV*DG(Luc) replicon assay, it was possible to quantify the
antiviral activity of IFN-l (Il-29), a type III IFN. This raises the
important question of how to distinguish between different
antiviral cytokines? Certainly, neutralizing antibodies may be
employed to specify the antiviral cytokine present in the sample. In
addition, the extraordinary acid-stability of type I IFNs may be
used to differentiate them from acid-labile cytokines such as type II
IFNs [35]. However, acid may not be used to distinguish between
type I and type III IFNs as IFN-l proved to be acid-stable as well.
Since IFN-l but not IFN-b was sensitive to 0.1 M NaOH,
treatment with alkaline may be used instead. However, the
conditions of treatment still have to be optimized to guarantee the
complete inactivation of type III IFNs while maintaining the
activity of type I IFNs.
In addition to antiviral cytokines, test samples may also contain
unknown viruses that potentially interfere with the bioassay.
Treatment with heat or acid may be used to inactivate these
viruses without affecting the bioactivity of type I and type III IFNs.
However, as heat-inactivated influenza viruses still may be able to
induce type I IFN [36], virus inactivation by acid may be more
convenient.
The correct and reliable determination of type I IFN biological
activity is an important issue. The new bioassay presented in this
study represents an attractive alternative to conventional type I
IFN bioassays that work with cytotoxic live viruses. VSV*DG(Luc)
is easily produced and handled under BSL-1 conditions. The
activity of the replicon can be easily determined and standardized
taking advantage of the two reporter proteins. It may be stored for
prolonged time in lyophilized form without losing its activity.
Finally, the proven sensitivity, rapidity, and accurateness of the
assay recommends it for the determination of type I IFN from a
number of mammalian and avian species. Finally, the test may be
further developed to quantify the antiviral activity of other
cytokines such as type II and type III IFNs.
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